Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept

In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences. In addition to commercially available afliberce...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira Dias, João Rafael, de Andrade, Gabriel Costa, Novais, Eduardo Amorim, Farah, Michel Eid, Rodrigues, Eduardo Büchele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088480/
https://www.ncbi.nlm.nih.gov/pubmed/27847621
http://dx.doi.org/10.1186/s40942-016-0026-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088480/
https://www.ncbi.nlm.nih.gov/pubmed/27847621
http://dx.doi.org/10.1186/s40942-016-0026-y

Ejemplares similares